Figure 12 Development of squamous cell carcinoma during treatment with vemurafenib (BRAF-inhibitor) These findings highlight how this website familiarity with the characteristic skin reactions observed in classes or families of targeted chemotherapeutics may help predict what reactions to expect from new agents. Knowledge of the presentation and treatment of the cutaneous toxicities caused by targeted

therapies approved for the treatment of colorectal cancers is extremely important for the practicing oncologist and dermatologist. Inhibitors,research,lifescience,medical Successful treatment improves patients’ quality of life while undergoing these therapies. It addition, by minimizing the cutaneous side effects patients experience these life-saving treatments can be continued at the proper doses and durations to allow for the most effective treatment of their cancers. Acknowledgements Disclosure: Dr. Urban

has no conflicts of interest or financial interests to report. Dr. Anadkat has received honoraria for consulting and/or speaking in the past from ImClone, Bristol-Myers Squibb, Astra-Zeneca, Inhibitors,research,lifescience,medical Eisai, and Therakos.
Before surgical advances allowed safe resection of colorectal liver metastases (CRLM), patients Inhibitors,research,lifescience,medical were treated primarily with systemic therapies. In fact, over two decades have passed since bolus 5-fluorouracil (5-FU) was the standard of care for patients with mCRC (8-10). Variations in the administration of 5-FU and combinations with agents to modulate its activity Inhibitors,research,lifescience,medical [levamisole and leucovorin (LV)] produced incremental improvements in patient outcomes; however, median overall survival (OS) largely remained near 12 months (11-14). A major

advance in systemic therapies for mCRC was reported in 2000 when two phase III trials showed that the addition of irinotecan (CPT-11), a DNA topoisomerase I inhibitor, to 5-FU/LV significantly increased overall response rates (ORR), progression-free survival (PFS), and OS (15-17). In the report by Saltz et al., weekly treatment consisted of irinotecan (125 mg/m2), bolus 5-FU (500 mg/m2), and LV (20 mg/m2) (IFL) (15). In the 2nd trial, Douillard et al., observed improved outcomes Inhibitors,research,lifescience,medical using all bi-weekly FOLFIRI (irinotecan, 180 mg/m2; LV, 200 mg/m2; and bolus 5-FU, 400 mg/m2 followed by 22 h infusional 5-FU, 600 mg/m2) (16). These positive studies led to the acceptance of the combination of irinotecan with 5-FU/LV for first-line therapy of mCRC. During the same period of time that improvements with irinotecan were observed, oxaliplatin, a platinum-based agent that blocks DNA replication, was also tested in combination with 5-FU/LV (FOLFOX) for patients with mCRC (18). In a phase III study reported by de Gramont et al., patients who were administered FOLFOX4 (LV, 200 mg/m2; 5-FU, 400 mg/m2 bolus followed by 22 h infusion of 600 mg/m2; and oxaliplatin, 85 mg/m2) had improved ORR and prolonged PFS, although increases in OS did not reach statistical significance (19).